MX367563B - Composición antitranspirante. - Google Patents

Composición antitranspirante.

Info

Publication number
MX367563B
MX367563B MX2017012019A MX2017012019A MX367563B MX 367563 B MX367563 B MX 367563B MX 2017012019 A MX2017012019 A MX 2017012019A MX 2017012019 A MX2017012019 A MX 2017012019A MX 367563 B MX367563 B MX 367563B
Authority
MX
Mexico
Prior art keywords
antiperspirant composition
specified protein
composition
reducing
orai3
Prior art date
Application number
MX2017012019A
Other languages
English (en)
Other versions
MX2017012019A (es
Inventor
Bovell Douglas
Livesey Evans Richard
Robertson Jennifer
Original Assignee
Unilever Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Nv filed Critical Unilever Nv
Publication of MX2017012019A publication Critical patent/MX2017012019A/es
Publication of MX367563B publication Critical patent/MX367563B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un método para reducir la transpiración que comprende la aplicación tópica de una composición que comprende un siRNA que es capaz de reducir los niveles de una proteína especificada o su mRNA o la función o formación del canal de calcio asociado con este; en donde la proteína especificada es Orai1, Stim1, Orai3, TRPC1 o Stim2.
MX2017012019A 2015-03-20 2016-03-10 Composición antitranspirante. MX367563B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15160174 2015-03-20
PCT/EP2016/055157 WO2016150723A1 (en) 2015-03-20 2016-03-10 Antiperspirant composition

Publications (2)

Publication Number Publication Date
MX2017012019A MX2017012019A (es) 2018-01-30
MX367563B true MX367563B (es) 2019-08-27

Family

ID=52686284

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012019A MX367563B (es) 2015-03-20 2016-03-10 Composición antitranspirante.

Country Status (6)

Country Link
US (1) US10227594B2 (es)
EP (1) EP3270881B1 (es)
AU (1) AU2016236521B2 (es)
BR (1) BR112017018029B1 (es)
MX (1) MX367563B (es)
WO (1) WO2016150723A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL316195A (en) 2017-12-15 2024-12-01 Flagship Pioneering Innovations Vi Llc Preparations containing circular polyribonucleotides and uses thereof
WO2020072942A1 (en) * 2018-10-04 2020-04-09 The Trustees Of Indiana University Methods to treat renal disorders using calcium channel inhibitors
MA55083A (fr) * 2019-03-01 2022-03-16 Flagship Pioneering Innovations Vi Llc Polyribonucléotides et leurs utilisations cosmétiques
CN113661242A (zh) 2019-03-25 2021-11-16 旗舰创业创新第六有限责任公司 包含经修饰的环状多核糖核苷酸的组合物及其用途
MX2023014480A (es) 2021-06-07 2023-12-15 Unilever Ip Holdings B V Composiciones y metodos para controlar la produccion de sudor.
WO2024104663A1 (en) 2022-11-16 2024-05-23 Unilever Ip Holdings B.V. Method of reducing malodour

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2797447B1 (fr) 1999-08-12 2004-04-02 Univ Clermont Auvergne "odorant-binding" proteines humaines fixant des ligands hydrophobes:polypeptides et polynucleotides codant lesdits polypeptides et leurs applications
FR2804960B1 (fr) 2000-02-11 2005-06-24 Lvmh Rech Nouveaux oligonucleotides et utilisation d'oligonucleotides modulant l'expression de la tyrosinase et de la tyrosinase- related-protein 1 comme agents depigmentants
GB0019055D0 (en) 2000-08-03 2000-09-27 Unilever Plc Antiperspirant and deodorant products and methods for their use
FR2840217B1 (fr) 2002-06-03 2005-06-24 Oreal Compositions cosmetiques comprenant au moins un oligonucleotide d'arn double brin (dsrna)et leurs utilisations
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US7504385B2 (en) 2003-12-17 2009-03-17 Avon Products, Inc. si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation
DE102004010547A1 (de) 2004-03-03 2005-11-17 Beiersdorf Ag Oligoribonukleotide zur Behandlung von irritativen und/oder entzündlichen Hauterscheinungen durch RNA-Interferenz
EP1752536A4 (en) 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
EP1814996A2 (en) 2004-11-19 2007-08-08 Novozymes A/S Polypeptides having antimicrobial activity and polynucleotides encoding same
DE102005001784A1 (de) 2005-01-13 2006-10-05 Beiersdorf Ag Oligoribonukleotide zur Reduktion der Schweißbildung durch RNA-Interferenz
US7534762B2 (en) 2005-03-18 2009-05-19 Novozymes A/S Polypeptides having antimicrobial activity and polynucleotides encoding same
FR2890859B1 (fr) 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
CN101340884A (zh) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
AR057240A1 (es) 2005-12-14 2007-11-21 Novozymes As Polipeptidos que presentan actividad antimicrobiana y polinucleotidos que los codifican
WO2009001359A2 (en) 2007-06-27 2008-12-31 Quark Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of pro-apoptotic genes
WO2009051439A2 (en) 2007-10-18 2009-04-23 Amorepacific Corporation Method of identifying agents which modulate the activity of calcium-activated chloride channel
AU2008314628B2 (en) 2007-10-18 2014-03-06 Rose U Topical glycopyrrolate formulations
WO2010080452A2 (en) 2008-12-18 2010-07-15 Quark Pharmaceuticals, Inc. siRNA COMPOUNDS AND METHODS OF USE THEREOF
FR2948021A1 (fr) 2009-07-16 2011-01-21 Oreal Utilisation cosmetique de polypeptides de type lacritine
WO2013120726A2 (en) 2012-02-13 2013-08-22 Unilever N.V. A skin lightening composition
US9809853B2 (en) 2012-08-16 2017-11-07 Brain Biotechnology Research And Information Network Ag Calcium-activated chloride channel involved in human sweat formation
EP2958572B1 (en) 2013-01-03 2019-10-23 Hidros Therapeutics International AB Treatment of hyperhidrosis
EP2865758A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene

Also Published As

Publication number Publication date
EP3270881A1 (en) 2018-01-24
EP3270881B1 (en) 2018-12-26
WO2016150723A1 (en) 2016-09-29
AU2016236521A1 (en) 2017-09-07
US20180037894A1 (en) 2018-02-08
BR112017018029A2 (pt) 2018-04-10
MX2017012019A (es) 2018-01-30
US10227594B2 (en) 2019-03-12
BR112017018029B1 (pt) 2021-06-15
AU2016236521B2 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
MX2017012019A (es) Composicion antitranspirante.
EP3730579B8 (en) Composition containing refrigerant, use of said composition, refrigerator having said composition, and method for operating said refrigerator
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12018501159A1 (en) Composition and methods for immunooncology
PH12018500906B1 (en) Antibodies specifically binding pd-1 and their uses
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
HK1216859A1 (zh) Irak抑制劑和其用途
EP3081546A4 (en) Rapid-setting and hardening, high-belite sulfoaluminate cement clinker as well as application and production process thereof
MX377710B (es) Anticuerpos monoclonales contra bcma.
SG10201902326XA (en) Mk2 inhibitors and uses thereof
HK1254880A1 (zh) 抗pd-1抗体及其应用
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
HK1210732A1 (en) Irak inhibitors and uses thereof
AU2016263598A8 (en) Methods and kits for treating depression
EA033325B1 (ru) Ингибиторы бромодомена
EP3258966A4 (en) Methods, compositions, and kits for treatment of cancer
EP4361178A3 (en) Acid-alpha glucosidase variants and uses thereof
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
EP4616910A3 (en) Pcna inhibitors
EP3312151A4 (en) Oxidation-induced self-healing ceramic composition containing healing activator, method for producing same, use of same, and method for enhancing functionality of oxidation-induced self-healing ceramic composition
EP3585376A4 (en) CALCIUM CHANNELS INHIBITORS
WO2018226992A8 (en) Tau aggregation inhibitors
PH12018500203B1 (en) Anti-cd154 antibodies and methods of using them
HK1250649A1 (zh) 用於治疗白血病的抗-s100a8

Legal Events

Date Code Title Description
FG Grant or registration